These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36644222)

  • 1. Psychiatric comorbidities and their treatment predict buprenorphine continuation among postpartum people with opioid use disorder.
    Shadowen H; Violante S; Gataric A; Goulding AN; Martin CE
    Drug Alcohol Depend Rep; 2022 Dec; 5():. PubMed ID: 36644222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
    Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
    Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Integrated Care Model for Pregnant and Postpartum Individuals Receiving Medication for Opioid Use Disorder.
    Ellis LP; Parlier-Ahmad AB; Scheikl M; Martin CE
    J Addict Med; 2023 Mar-Apr 01; 17(2):131-139. PubMed ID: 35972153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receipt and duration of buprenorphine treatment during pregnancy and postpartum periods in a national privately-insured cohort.
    Wang X; Meisel Z; Kellom K; Whitaker J; Strane D; Chatterjee A; Rosenquist R; Matone M
    Drug Alcohol Depend Rep; 2023 Dec; 9():100206. PubMed ID: 38045493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incarceration status at buprenorphine initiation and OUD treatment outcomes during pregnancy.
    Nguyen A; Shadowen H; Shadowen C; Thakkar B; Knittel AK; Martin CE
    Front Psychiatry; 2023; 14():1157611. PubMed ID: 37124262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Pregnancy Recovery Center: A women-centered treatment program for pregnant and postpartum women with opioid use disorder.
    Krans EE; Bobby S; England M; Gedekoh RH; Chang JC; Maguire B; Genday P; English DH
    Addict Behav; 2018 Nov; 86():124-129. PubMed ID: 29884421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims.
    Xu KY; Huang V; Williams AR; Martin CE; Bazazi AR; Grucza RA
    Drug Alcohol Depend Rep; 2023 Dec; 9():100195. PubMed ID: 38023343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of chronic non-cancer pain status and buprenorphine treatment retention among individuals with opioid use disorder: Results from electronic health record data.
    John WS; Mannelli P; Hoyle RH; Greenblatt L; Wu LT
    Drug Alcohol Depend Rep; 2022 Jun; 3():100048. PubMed ID: 36845986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
    Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
    JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for preterm birth among gravid individuals receiving buprenorphine for opioid use disorder.
    Abdelwahab M; Petrich M; Wang H; Walker E; Cleary EM; Rood KM
    Am J Obstet Gynecol MFM; 2022 May; 4(3):100582. PubMed ID: 35123110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
    Sujan A; Cleary E; Douglas E; Aujla R; Boyars L; Smith C; Guille C
    Fam Pract; 2022 Mar; 39(2):311-315. PubMed ID: 34537839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
    Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
    Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention.
    Ray-Griffith S; Tharp E; Coker JL; Catlin D; Knight B; Stowe ZN
    Am J Addict; 2021 Jan; 30(1):43-48. PubMed ID: 32673447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder.
    Parlier-Ahmad AB; Pugh M; Martin CE
    J Racial Ethn Health Disparities; 2022 Aug; 9(4):1557-1567. PubMed ID: 34254271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.
    Calcaterra SL; Lockhart S; Callister C; Hoover K; Binswanger IA
    J Gen Intern Med; 2022 Aug; 37(11):2786-2794. PubMed ID: 34981359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery.
    Nielsen T; Bernson D; Terplan M; Wakeman SE; Yule AM; Mehta PK; Bharel M; Diop H; Taveras EM; Wilens TE; Schiff DM
    Addiction; 2020 Feb; 115(2):291-301. PubMed ID: 31692133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.